Arcadia Biosciences, Inc. filed 8-K

Arcadia Biosciences, Inc. files 8-K in a filing on Sep 13, 2019.

Item 5.02. Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 11, 2019, Arcadia Biosciences, Inc. (the ‘Company’) received notification from Eric Rey of his resignation as a member of the Company’s board of directors, effective September 30, 2019.

On May 20, 2019, the Company received a notification letter from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company’s Market Value of Listed Securities did not maintain a minimum value of $35 million for 30 consecutive business days as required by Nasdaq Listing Rule 5550(b)(2) (the ‘Rule’).

On September 12, 2019, the Company received a notification letter from Nasdaq indicating that the Company’s Market Value of Listed Securities has been $35 million or greater for the last ten consecutive business days. Accordingly, the Company has regained compliance with the Rule and this matter is now closed.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.